Related Experiment Video

Updated: Apr 12, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.7K

Targeting FGF receptors in colorectal cancer: from bench side to bed side

Omar Abdel-Rahman

    Future Oncology (London, England)
    |May 9, 2015
    PubMed

    Insights

    Targeted therapies for advanced colorectal cancer are improving treatment outcomes. This review focuses on fibroblast growth factor receptor (FGFR) pathway inhibitors and their future potential in managing this challenging disease.

    Area of Science:

    • Oncology
    • Molecular Biology
    • Pharmacology

    Background:

    • Advanced colorectal cancer (CRC) management remains a significant clinical challenge.
    • Advances in understanding CRC pathobiology have identified critical molecular targets.
    • The fibroblast growth factor receptor (FGFR) pathway is implicated in CRC progression.

    Purpose of the Study:

    • To review biological and clinical aspects of FGFR pathway-targeted therapies in advanced CRC.
    • To discuss the current status and future perspectives of these targeted therapies.

    Main Methods:

    • Literature review of preclinical and clinical studies.
    • Analysis of biological mechanisms involving FGFR signaling in CRC.
    • Evaluation of clinical trial data for FGFR inhibitors in advanced CRC.

    Main Results:

    • FGFR pathway dysregulation is observed in a subset of advanced CRC.
    • Early clinical data suggest potential efficacy of FGFR inhibitors in specific CRC populations.
    • Resistance mechanisms to FGFR inhibitors require further investigation.

    Conclusions:

    • FGFR pathway-targeted therapies represent a promising new avenue for advanced CRC treatment.
    • Personalized approaches based on FGFR pathway status are crucial for optimal patient selection.
    • Further research is needed to overcome resistance and optimize therapeutic strategies.
    Keywords:
    FGFRbrivanibgastrointestinal cancerregorafenib

    More Related Videos

    A Three-dimensional Model of Spheroids to Study Colon Cancer Stem Cells06:38

    A Three-dimensional Model of Spheroids to Study Colon Cancer Stem Cells

    Published on: January 22, 2021

    7.1K
    Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library07:32

    Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

    Published on: September 30, 2019

    8.4K

    Related Concept Videos

    Mitogens and the Cell Cycle02:38

    Mitogens and the Cell Cycle

    Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
    8.5K
    Transducer Mechanism: G Protein–Coupled Receptors01:30

    Transducer Mechanism: G Protein–Coupled Receptors

    G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
    GPCRs are also called heptahelical,...
    8.6K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    9.2K
    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
    69